FDA Delays Decision on Moderna Vaccine for Adolescents Citing Heart Problems, Yet Pfizer Authorized for Teens, Despite Higher Number of Myocarditis Reports • Children's Health Defense

The U.S. Food and Drug Administration (FDA) said on Oct. 15 it was delaying a decision on authorizing Moderna’s COVID vaccine for adolescents.

FDA Delays Decision on Moderna Vaccine for Adolescents Citing Heart Problems, Yet Pfizer Authorized for Teens, Despite Higher Number of Myocarditis Reports

The Pfizer and Moderna COVID vaccines are both linked to heart inflammation. In May, the U.S. Food and Drug Administration authorized Pfizer’s vaccine for 12- to 17-year-olds, but the agency is delaying its decision on authorizing Moderna’s vaccine for adolescents while it assesses whether the shot could increase the risk of myocarditis.